Appendix Table 5.

Sensitivity Analysis Results for Best Strategies Model; 50% Lower Fracture Rates^*

Screening Strategy	Lifetime Cost, $†	Quality- Adjusted Life-Years Accrued	Incremental Cost- Effectiveness Ratio†
No screening	52 540	14.1859	NA
SCORE −2.5 initiated at age 80 y with rescreening every 5 y	52 710	14.1935	21 260
SCORE −2.5 initiated at age 70 y with rescreening every 10 y	52 930	14.2008	31 170
QUS −1.0 initiated at age 60 y with rescreening every 10 y	53 090	14.2042	46 380
SCORE −2.5 initiated at age 60 y with rescreening every 10 y	53 190	14.2061	48 990
QUS −1.0 initiated at age 55 y with rescreening every 5 y	53 400	14.2088	79 810
SCORE −2.5 initiated at age 55 y with rescreening every 5 y	53 510	14.2097	127 650
DXA −2.5 initiated at age 55 y with rescreening every 5 y	53 550	14.2099	151 080
DXA −2.0 initiated at age 55 y with rescreening every 10 y	54 140	14.2121	269 880
DXA −1.5 initiated at age 55 y with rescreening every 10 y	55 050	14.2132	831 330
DXA −1.5 initiated at age 55 y with rescreening every 5 y	55 280	14.2133	2 849 790

DXA = dual-energy x-ray absorptiometry; NA = not applicable; QUS = quantitative ultrasonography; SCORE = Simple Calculated Osteoporosis Risk Estimation.

^*Strategies are described in Table 1. Costs are expressed in 2010 $US, and incremental cost-effectiveness ratios represent cost per quality-adjusted life-year gained for each strategy compared to the next less costly nondominated strategy.

^†Costs and incremental cost-effectiveness ratios are rounded off to the nearest 10.